Research ArticleHuman Studies
Somatostatin Receptor Scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-Tyr-3-Octreotide
E.P. Krenning, W.H. Bakker, P.P.M. Kooij, W.A.P. Breeman, H.Y. Oei, M. de Jong, J.C. Reubi, T.J. Visser, C. Bruns, D.J. Kwekkeboom, A.E.M. Reijs, P.M. van Hagen, J.W. Koper and S.W.J. Lamberts
Journal of Nuclear Medicine May 1992, 33 (5) 652-658;
E.P. Krenning
W.H. Bakker
P.P.M. Kooij
W.A.P. Breeman
H.Y. Oei
M. de Jong
J.C. Reubi
T.J. Visser
C. Bruns
D.J. Kwekkeboom
A.E.M. Reijs
P.M. van Hagen
J.W. Koper


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Somatostatin Receptor Scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-Tyr-3-Octreotide
E.P. Krenning, W.H. Bakker, P.P.M. Kooij, W.A.P. Breeman, H.Y. Oei, M. de Jong, J.C. Reubi, T.J. Visser, C. Bruns, D.J. Kwekkeboom, A.E.M. Reijs, P.M. van Hagen, J.W. Koper, S.W.J. Lamberts
Journal of Nuclear Medicine May 1992, 33 (5) 652-658;
Somatostatin Receptor Scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-Tyr-3-Octreotide
E.P. Krenning, W.H. Bakker, P.P.M. Kooij, W.A.P. Breeman, H.Y. Oei, M. de Jong, J.C. Reubi, T.J. Visser, C. Bruns, D.J. Kwekkeboom, A.E.M. Reijs, P.M. van Hagen, J.W. Koper, S.W.J. Lamberts
Journal of Nuclear Medicine May 1992, 33 (5) 652-658;
Jump to section
Related Articles
- No related articles found.
Cited By...
- 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
- 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
- Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
- Treatment Outcomes in Neuroendocrine Prostate Cancer
- Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas
- Somatostatin Receptor Scintigraphy: Blazing in Indium and Quenching in Gallium (perspective on "Somatostatin Receptor Scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-Tyr-3-Octreotide" J Nucl Med. 1992;33:652-658)
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting
- Somatostatin Receptor 2-Targeting Compounds
- Management of neuroendocrine tumors
- Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine Xenografts
- 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
- Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE Therapy
- 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
- Preclinical SPECT/CT Imaging of {alpha}v{beta}6 Integrins for Molecular Stratification of Idiopathic Pulmonary Fibrosis
- Measured Human Dosimetry of 68Ga-DOTATATE
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- Patient-Specific Dosimetry Calculations Using Mathematic Models of Different Anatomic Sizes During Therapy with 111In-DTPA-D-Phe1-Octreotide Infusions After Catheterization of the Hepatic Artery
- Gluc-Lys([18F]FP)-TOCA PET in Patients with SSTR-Positive Tumors: Biodistribution and Diagnostic Evaluation Compared with [111In]DTPA-Octreotide
- Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium
- Therapeutic Efficacy of a 188Re-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models
- Long-Term Efficacy of Radionuclide Therapy in Patients with Disseminated Neuroendocrine Tumors Uncontrolled by Conventional Therapy
- Uptake of [111In-DTPA0]Octreotide in the Rat Kidney Is Inhibited by Colchicine and Not by Fructose
- 110mIn-DTPA-D-Phe1-Octreotide for Imaging of Neuroendocrine Tumors with PET
- 64Cu-TETA-Octreotide as a PET Imaging Agent for Patients with Neuroendocrine Tumors
- Somatostatin Receptor Scintigraphy in the Initial Staging of Low-Grade Non-Hodgkin's Lymphomas
- Value of Peptide Receptor Scintigraphy Using 123I-Vasoactive Intestinal Peptide and 111In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998
- Radiotherapy and Dosimetry of 64Cu-TETA-Tyr3-Octreotate in a Somatostatin Receptor-positive, Tumor-bearing Rat Model
- In Vivo Localization of [111In]-DTPA-D-Phe -Octreotide to Human Ovarian Tumor Xenografts Induced to Express the Somatostatin Receptor Subtype 2 Using an Adenoviral Vector
- Design and characterization of {alpha}-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination
- Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study
- Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumors